Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
Healthcare · Biotech & pharma
SMT112-216 Is a Randomized Multiregional Phase II Study Evaluating Ivonescimab Alone and in Combination with Cadonilimab or Ipilimumab in Previously Untreated Advanced ccRCC Study Is Being Conducted in Collaboration with Summit's Partner Akeso, with Clinical Trial Sites in the U.S. and China MIAMI, October 19, 2026 --( BU
Oct 19 · 11:00·Business Wire
Finance · Biotech & pharma
Transaction Includes Concurrent $160 million Private Investment in Public Equity (PIPE) Financing and Expected Gross Proceeds of Approximately $246 million NEW YORK & PALO ALTO, Calif., October 19, 2026--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class t
Oct 19 · 11:00·Business Wire
Healthcare · Biotech & pharma
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 VDPHL01 demonstrated increases in target area hair count (TAHC) of
Oct 19 · 11:00·Business Wire
Healthcare · Biotech & pharma
CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of CLDN18.2-positive gastric cancer patients SAFFRON results will highlight clinical benefit of adding savolitinib to backbone TAGRISSO in MET-driven 2nd-line EGFRm lung cancer VOLGA and DeLLphi-305 data will showc
Oct 19 · 11:00·Business Wire
Healthcare · Food & drink
KOLDING, Denmark, 2026-10-19 — Unplanned downtime remains one of the biggest hidden costs in food, beverage, dairy, pharma and other hygienic industries. [read full press release...]
Oct 19 · 10:14·Express Press Release
Biotech & pharma
The Antibody Drug Conjugates Market is covered by Business Market Insights with 2025 as the base year and 2026–2033 as the forecast period. The Antibody Drug Conjugates Market size was valued at US$ 21.27 Billion in 2025 and is projected ...
Read more
Oct 19 · 10:13·PR News Releaser
AI · Biotech & pharma
Dublin, Oct. 19, 2026 -- "United States Smart Pills Market - Drug Delivery Innovation & Forecast 2026-2034" has been added to ResearchAndMarkets.com's offering.
Oct 19 · 10:12·GlobeNewswire
Healthcare · Biotech & pharma
OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of HLA-A*02:01 allele status or line of therapy OptimUM-01 data demonstrates encouraging clinical...
Oct 19 · 10:00·PR Newswire
Finance · Biotech & pharma
VANCOUVER, British Columbia , Oct. 19, 2026 -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that Suzanne Monahan has been appointed Senior Vice President, Commercial and General Manager, Theravance Biopharma, effective immediately. Reporting directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, Ms. Monahan will lead Zymeworks’ commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of chronic obstructive pulmonary disease (COPD), following the Company’s recent acquisition of Theravance Biopharma.
Oct 19 · 10:00·GlobeNewswire
Biotech & pharma
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 -- TLC BioSciences Corp. (TPEx: TLC-KY; ticker: 7924; “TLC”) today announced positive topline results from its pivotal Phase 3 trial of TLC590, an investigational extended-release formulation of ropivacaine, for the management of postsurgical pain following bunionectomy. The trial met its primary endpoint, with TLC590 significantly reducing pain intensity through 72 hours after surgery compared with placebo (p=0.0024); rescue opioid consumption was also significantly lower. In a head-to-head comparison with liposomal bupivacaine, an approved long-acting local anesthetic, TLC590 also demonstrated statistically significant superiority in both pain intensity and rescue opioid consumption. The analgesic benefit of TLC590 over both comparators was maintained through 168 hours. These results support the potential of TLC590 as a single-dose, non-opioid option for durable postsurgical pain relief with reduced opioid use.
Oct 19 · 10:00·GlobeNewswire
Finance · Healthcare
SAN DIEGO, Oct. 19, 2026 -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has received approval from Nasdaq to transfer the listing of its securities from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market will commence at the open of market on October 19, 2026, under the Company’s existing ticker symbol “BLTE.”
Oct 19 · 10:00·GlobeNewswire
Biotech & pharma
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne's solid tumor pipeline Multiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data
Oct 19 · 10:00·Business Wire